Pfizer
Pfizer's revenue fell 1.6% to $62.6 billion in fiscal 2025. Its net margin was 12.4%, down from 12.6% a year earlier. Free cash flow was $9.1 billion, down 7.7%. It paid out $9.8 billion in dividends and buybacks, 108% of free cash flow. The diluted share count rose 0.2%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Pfizer does
Pfizer discovers, develops, makes and sells prescription medicines and vaccines, and supplies them to about 200 countries and territories. Its products include Eliquis, part of its internal medicine portfolio, vaccines such as the Prevnar family, Comirnaty and Abrysvo, the COVID-19 treatment Paxlovid, and cancer drugs such as Ibrance, Xtandi and Padcev. It sells its medicines mainly to wholesalers, and also directly to retailers, hospitals, clinics, pharmacies and government agencies.
Most of Pfizer's revenue comes from making and selling these products, and Biopharma is its only reportable segment. It also runs PC1, which develops and manufactures drugs for other companies under contract. In 2025, 12 products each brought in more than $1 billion, together 65% of total revenue; Eliquis alone was 13%. Revenue from outside the U.S. was $25.5 billion, or 41% of the total. Pfizer says it competes with other global drug companies, smaller research companies, and makers of generic drugs and biosimilars, which are close, lower-cost versions of biologic medicines.
Pfizer employed about 75,000 people at the end of 2025. In November 2025 it bought Metsera, a company developing medicines for obesity and related heart and metabolic diseases that are still in clinical trials. In 2025 it also decided to wind down Pfizer Ignite, which provided research services to biotech companies, and at the start of 2026 it set up a new Global Hospital and Biosimilars organization.
Its biggest risks, as it describes them
- Losing sales when patents and exclusivity rights expire and cheaper generic drugs or biosimilars reach the market.
- Its reliance on a small group of large products, such as Eliquis, and on a few large customers for much of its revenue.
- Pressure on drug prices from governments, insurers and benefit managers, including its voluntary deal with the U.S. government to lower prices.
- Acquisitions and other deals, such as its purchase of Metsera, may not bring the benefits it expects.
- Competing products from other drugmakers that could cut into sales of its current and future medicines.
Income statement
From fiscal 2016 to 2025, earnings per share grew 1.7% a year and net income 0.8% a year, as buybacks cut the share count by 7%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 24.0 | 19.2 | 7.3 | 11.9 | 10.3 |
| Debt incl. finance leases | 37.8 | 35.4 | 71.8 | 63.6 | 64.6 |
| Net debt (negative means net cash) | 13.9 | 16.3 | 64.5 | 51.7 | 54.3 |
| Net debt to EBITDA | 0.5x | 0.4x | 6.8x | 2.9x | 3.2x |
| Debt to equity | 0.5x | 0.4x | 0.8x | 0.7x | 0.8x |
| Interest coverage | 19.8x | 29.1x | 1.5x | 3.6x | 3.8x |
| Current ratio | 1.4x | 1.2x | 0.9x | 1.2x | 1.2x |
| Quick ratio | 1.2x | 1.0x | 0.7x | 0.9x | 0.9x |
Cash flow
Projections
Project Pfizer's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Pfizer says to expect
- Full year 2026: revenues
Raises full-year 2026 Revenue guidance (2) by $1.5 billion at the midpoint to a range of $62.0 to $64.0 billion from $60.5 to $62.5 billion previously.
- Full year 2026: adjusted diluted EPS
Raises and narrows full-year 2026 Adjusted (3) diluted EPS guidance (2) to a range of $2.95 to $3.05 from $2.80 to $3.00 previously.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $3.0 million of Pfizer shares on the open market, and 1 insider sold $134,661.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Albert BourlaChairman & CEO, Director | Bought | 38,000 | $26.34 | $1.0 million | Form 4 |
| Aug 5, 2026 | Ronald E BlaylockDirector | Bought | 39,231 | $25.46 | $998,821 | Form 4 |
| Aug 5, 2026 | Mortimer J BuckleyDirector | Bought | 37,632 | $25.52 | $960,369 | Form 4 |
| Aug 5, 2026 | Jennifer B. DamicoSVP & Controller | Sold | 3,278 | $25.40 | $83,261 | Form 4 |
| Jun 9, 2026 | Jennifer B. DamicoSVP & Controller | Sold | 2,000 | $25.70 | $51,400 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 8 of 9 | 6 of 9 |
| Rule of 40 | −33.1% | 22.3% | 12.8% |
| Altman Z'' | 2.35 | 3.10 | 3.06 |
| Accruals ratio | −3.1% | −2.1% | −1.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Pass | Pass | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 4 of 9 | 8 of 9 | 6 of 9 |
Compare
Put Pfizer side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Pfizer | FY25 | −1.6% | — | 14.5% | 7.2% | 3.2x | 6 | |
| Johnson & Johnson | FY25 | 6.0% | — | 20.9% | 28.6% | 0.7x | 4 | Compare |
| AbbVie | FY25 | 8.6% | 24.6% | 29.1% | 15.7% | 2.7x | 7 | Compare |
| Moderna | FY25 | −39.9% | −158.1% | −106.2% | −65.4% | — | 2 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 52.8 | 52.5 | 40.8 | 40.9 | 41.7 | 81.3 | 101.2 | 59.6 | 63.6 | 62.6 |
| Revenue growth | 8.1% | −0.5% | −22.3% | 0.2% | 1.8% | 95.2% | 24.5% | −41.1% | 6.8% | −1.6% |
| Gross profit | 40.5 | 41.3 | 31.8 | 32.9 | 33.2 | 50.5 | 66.8 | 34.6 | 45.8 | 46.5 |
| Research and development | 7.9 | 7.7 | 7.8 | 8.4 | 8.7 | 10.4 | 11.4 | 10.7 | 10.8 | 10.4 |
| Operating income | — | — | — | — | — | — | — | — | — | — |
| Net income | 7.2 | 21.3 | 11.2 | 16.0 | 9.2 | 22.0 | 31.4 | 2.1 | 8.0 | 7.8 |
| Diluted EPS (US$) | 1.17 | 3.52 | 1.87 | 2.82 | 1.63 | 3.85 | 5.47 | 0.37 | 1.41 | 1.36 |
| Diluted shares (millions) | 6,159 | 6,058 | 5,977 | 5,675 | 5,632 | 5,708 | 5,733 | 5,709 | 5,700 | 5,713 |
| Cash flow | ||||||||||
| Cash from operations | 16.2 | 16.8 | 15.8 | 12.6 | 14.4 | 32.6 | 29.3 | 8.7 | 12.7 | 11.7 |
| Capital expenditure | 1.8 | 2.0 | 2.0 | 2.0 | 2.2 | 2.7 | 3.2 | 3.9 | 2.9 | 2.6 |
| Free cash flow | 14.4 | 14.8 | 13.8 | 10.5 | 12.2 | 29.9 | 26.0 | 4.8 | 9.8 | 9.1 |
| Dividends paid | 7.3 | 7.7 | 8.0 | 8.0 | 8.4 | 8.7 | 9.0 | 9.2 | 9.5 | 9.8 |
| Share buybacks | 5.0 | 5.0 | 12.2 | 8.9 | 0.0 | 0.0 | 2.0 | 0.0 | 0.0 | 0.0 |
| Acquisitions | 18.4 | 1.0 | 0.0 | 10.9 | 0.0 | 0.0 | 23.0 | 43.4 | 0.0 | 6.9 |
| Stock-based compensation | 0.7 | 0.8 | 0.9 | 0.7 | 0.8 | 1.2 | 0.9 | 0.5 | 0.9 | 0.8 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 17.9 | 20.0 | 18.8 | 9.6 | 11.5 | 24.0 | 19.2 | 7.3 | 11.9 | 10.3 |
| Debt incl. finance leases | 37.2 | 43.2 | 40.8 | 51.3 | 4.6 | 37.8 | 35.4 | 71.8 | 63.6 | 64.6 |
| Total assets | 171.6 | 171.8 | 159.4 | 167.6 | 154.2 | 181.5 | 197.2 | 226.5 | 213.4 | 208.2 |
| Total liabilities | 111.8 | 100.1 | 95.7 | 104.1 | 90.8 | 104.0 | 101.3 | 137.2 | 124.9 | 121.4 |
| Shareholders' equity | 59.5 | 71.3 | 63.4 | 63.1 | 63.2 | 77.2 | 95.7 | 89.0 | 88.2 | 86.5 |
| Margins and ratios | ||||||||||
| Gross margin | 76.7% | 78.6% | 78.0% | 80.3% | 79.6% | 62.1% | 66.0% | 58.1% | 71.9% | 74.3% |
| Operating margin | — | — | — | — | — | — | — | — | — | — |
| Net margin | 13.7% | 40.5% | 27.3% | 39.2% | 22.0% | 27.0% | 31.0% | 3.6% | 12.6% | 12.4% |
| Free cash flow margin | 27.2% | 28.2% | 33.9% | 25.8% | 29.2% | 36.7% | 25.7% | 8.1% | 15.5% | 14.5% |
| Rule of 40 (growth + FCF margin) | 35.3% | 27.7% | 11.6% | 26.0% | 31.1% | 131.9% | 50.2% | −33.1% | 22.3% | 12.8% |
| Return on capital | 11.0% | 15.6% | 5.4% | 12.8% | 9.9% | 32.0% | 32.0% | 2.5% | 7.6% | 7.2% |
| Return on equity | 11.6% | 32.6% | 16.6% | 25.3% | 14.5% | 31.3% | 36.3% | 2.3% | 9.1% | 8.9% |
| Return on assets | 4.3% | 12.4% | 6.7% | 9.8% | 5.7% | 13.1% | 16.6% | 1.0% | 3.6% | 3.7% |
| Net debt to EBITDA | 1.3x | 1.2x | 1.9x | 2.2x | −0.5x | 0.5x | 0.4x | 6.8x | 2.9x | 3.2x |